Achaogen (AKAOQ) Inactive 10-Q12 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	6-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'AKAO	'
Entity Registrant Name	'ACHAOGEN INC	'
Entity Central Index Key	'0001301501	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	17,680,647

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$84,937	$10,738
Contracts receivable	6,027	7,230
Prepaids and other current assets	161	1,873
Total current assets	91,125	19,841
Property and equipment, net	662	743
Restricted cash	127	127
Deposit and other assets	44	47
Total assets	91,958	20,758
Current liabilities:	'	'
Accounts payable	4,544	2,923
Accrued liabilities	2,832	3,004
Notes payable, current portion	5,540	4,989
Other current liabilities	64	73
Total current liabilities	12,980	10,989
Deferred rent	133	125
Notes payable, noncurrent portion	'	1,698
Other long-term liabilities	'	244
Total liabilities	13,113	13,056
Commitments and contingencies	'	'
Convertible preferred stock, $0.001 par value, zero shares and 132,202,910 shares authorized at March 31, 2014 and December 31, 2013, respectively; zero shares and 9,796,342 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	'	132,278
Stockholders' equity (deficit)	'	'
Common stock, $0.001 par value, 290,000,000 and 163,000,000 shares authorized at March 31, 2014 and December 31, 2013, respectively; 17,680,647 and 392,844 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	18	'
Preferred stock, $0.001 par value, 10,000,000 shares and zero shares authorized at March 31, 2014 and December 31, 2013, respectively; zero shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	'	'
Additional paid-in-capital	211,006	4,148
Accumulated deficit	-132,179	-128,724
Total stockholders' equity (deficit)	78,845	-124,576
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)	$91,958	$20,758

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	132,202,910
Convertible preferred stock, shares issued	0	9,796,342
Convertible preferred stock, shares outstanding	0	9,796,342
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	290,000,000	163,000,000
Common stock, shares issued	17,680,647	392,844
Common stock, shares outstanding	17,680,647	392,844
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Contract revenue	$5,988	$3,533
Operating expenses	'	'
Research and development	6,605	4,661
General and administrative	2,617	2,154
Total operating expenses	9,222	6,815
Loss from operations	-3,234	-3,282
Interest expense and other, net	-221	-525
Interest income and other, net	'	54
Net loss and comprehensive loss	($3,455)	($3,753)
Basic and diluted net loss per common share	($1)	($10)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	3,456,088	375,321

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($3,455)	($3,753)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	88	180
Stock-based compensation expense	367	324
Revaluation of convertible preferred stock warrant liability	42	-54
Non-cash interest expense relating to notes payable	72	140
Non-cash interest expense relating to related-party convertible loan payable	'	197
Non-cash restructuring charges	'	196
Change in operating assets and liabilities:	'	'
Contracts receivable	1,203	-606
Prepaids and other assets	1,715	140
Accounts payable and accrued liabilities	211	175
Other liabilities	-1	-212
Net cash provided by (used in) operating activities	242	-3,273
Cash flows from investing activities:	'	'
Purchase of property and equipment	-7	-13
Net cash used in investing activities	-7	-13
Cash flows from financing activities:	'	'
Proceeds from issuance of convertible preferred stock	'	10,445
Proceeds from issuance of common stock	75,181	'
Proceeds from the exercise of stock warrants	2	'
Proceeds from the exercise of stock options, net of repurchases	'	27
Repayment of notes payable	-1,219	-1,123
Net cash provided by financing activities	73,964	9,349
Net increase in cash and cash equivalents	74,199	6,063
Cash and cash equivalents, beginning of period	10,738	7,073
Cash and cash equivalents, end of period	84,937	13,136
Supplemental disclosures of noncash investing and financing information	'	'
Conversion of related-party convertible loan and notes payable to convertible preferred stock	'	9,724
Conversion of convertible preferred stock into common stock	132,278	'
Reclassification of warrant liability to additional paid-in-capital	286	'
Deferred initial public offering issuance costs	$1,238	'

Organization_and_Basis_of_Pres

Organization and Basis of Presentation and Consolidation	3 Months Ended
Organization and Basis of Presentation and Consolidation	Mar. 31, 2014
Accounting Policies [Abstract]	'
Organization and Basis of Presentation and Consolidation	'
	1. Organization and Basis of Presentation and Consolidation
	Achaogen, Inc. (together with its consolidated subsidiary, the “Company”) is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). The Company initiated a Phase 3 superiority trial of plazomicin in the first quarter of 2014.
	The Company was incorporated in Delaware in 2002 and commenced operations in 2004. Since commencing operations in 2004, the Company has devoted substantially all of its resources to identifying and developing its product candidates, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations.
	Basis of Presentation and Consolidation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2013 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
	The accompanying condensed financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2013 included in the Company’s Prospectus filed pursuant to Rule 424(b)(4) on March 12, 2014 with the SEC (the “Prospectus”).
	Initial Public Offering
	In March 2014, the Company completed its initial public offering (“IPO”) of shares of its common stock, pursuant to which the Company issued 6,900,000 shares of common stock, which includes 900,000 shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately $73.9 million, after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the completion of our IPO, all shares of convertible preferred stock converted into 10,386,894 shares of common stock and all of the Company’s convertible preferred stock warrants were converted into warrants to purchase common stock.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Use of Estimates
	The accompanying financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent liabilities. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of liabilities, convertible preferred stock and related warrants, common stock and stock-based awards and income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.
	Reverse Stock Split
	On February 20, 2014, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-11 reverse split of its common stock (the “Reverse Split”). The Company effected this amendment to its certificate of incorporation on March 10, 2014. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to the condensed consolidated financial statements have been adjusted within the condensed consolidated financial statements, on a retroactive basis, to reflect the Reverse Split.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, contracts receivable, prepaid and other current assets, accounts payable, accrued liabilities, and certain related-party convertible notes payable approximate fair value due to their short-term maturities.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and other highly liquid investments with original maturities of three months or less from the date of purchase.
	Restricted Cash
	At March 31, 2014 and December 31, 2013, the Company had long-term restricted cash of $127,000. The restricted cash, which consists of a money market account with one of the Company’s financial institutions, serves as collateral for a letter of credit provided as a security deposit under the Company’s facility lease. The facility lease expires on April 14, 2017.
	Segment Reporting
	The Company has one operating segment.
	Customer Concentration
	For the three-month periods ended March 31, 2014 and 2013, all of the Company’s revenue has been generated solely from funding pursuant to U.S. government contracts, and accordingly all contracts receivable relate to funding from U.S. government contracts.
	Convertible Preferred Stock Warrant Liabilities
	The Company accounted for its Series A and Series C convertible preferred stock warrant liabilities as freestanding warrants for shares that are puttable or redeemable. At December 31, 2013, these warrants were classified as liabilities on the consolidated balance sheets at their estimated fair value, and at the end of each reporting period, changes in estimated fair value during the period were recorded as a component of interest expense and other, net. At the time of the IPO, the warrants to purchase preferred stock converted into warrants to purchase common stock, which are no longer subject to remeasurement.
	Revenue Recognition
	The Company recognizes revenue when: (i) evidence of an arrangement exists, (ii) fees are fixed or determinable, (iii) services have been delivered, and (iv) collectability is reasonably assured. The Company currently generates revenue entirely from government contracts. Government contracts are agreements that provide the Company with payments for certain types of expenditures in return for research and development activities over a contractually defined period. Revenue from government contracts is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the government contracts have been met.

	Funds received from third parties under contract arrangements are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from contracts are recorded as a reduction to research and development expense. Contracts funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds billed and received in advance are recorded as deferred revenue.
	Net Loss Per Share
	Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. For purposes of this calculation, preferred stock, stock options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Because the Company has reported a net loss in all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
	Effective as of the completion of the IPO, all of the Company’s preferred stock was converted to common stock. For purposes of calculating net loss per common share for the three-month period ended March 31, 2014, the preferred stock converted to common stock was included in the net loss per common share calculation on a post-conversion basis based on the conversion date.
	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):


		March 31,
		2014		2013
	Convertible preferred stock		—		9,404,574
	Warrants to purchase convertible preferred stock		—		40,454
	Options to purchase common stock		1,772,171		1,340,433
	Warrants to purchase common stock		40,454		909

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash and cash equivalents, contracts receivable, accounts payable, accrued liabilities, and certain related-party convertible notes approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
	Level 1: Quoted prices in active markets for identical assets or liabilities.
	Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

	The Company’s financial instruments have consisted of Level 1 assets and Level 3 liabilities. Where quoted prices are available in an active market, securities are classified as Level 1 of the valuation hierarchy. Level 1 securities include highly liquid money market funds and fixed- income securities issued by the U.S. government or its agencies.
	In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that are measured at estimated fair value on a recurring basis consist of convertible preferred stock warrant liabilities and derivative liabilities associated with certain convertible loans.
	The estimated fair value of the outstanding preferred stock warrant liability was measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value included the estimated fair value of the underlying preferred stock at the measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends on convertible preferred stock and expected volatility of the price of the underlying convertible preferred stock.
	During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at estimated fair value using Level 3 inputs, nor were there any transfers within the hierarchy.
	As of March 31, 2014 and December 31 2013, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):
	As of March 31, 2014:


		Level 1			Level 2		Level 3		Total
		(in thousands)
	Assets
	Cash	$	12,610		$	—	$	—	$	12,610
	Money market funds		72,327			—		—		72,327
	Restricted cash		127			—		—		127

		$	85,064		$	—	$	—	$	85,064

	Reported as:
	Cash and cash equivalents	$	84,937

	Restricted cash	$	127

	As of December 31, 2013:


		Level 1			Level 2		Level 3		Total
		(in thousands)
	Assets
	Cash	$	8,411		$	—	$	—	$	8,411
	Money market funds		2,327			—		—		2,327
	Restricted cash		127			—		—		127

		$	10,865		$	—	$	—	$	10,865

	Reported as:
	Cash and cash equivalents	$	10,738

	Restricted cash	$	127

	Liabilities
	Convertible preferred stock warrant liabilities	$	—		$	—	$	244	$	244

	In connection with the completion of the Company’s IPO in March 2014, all of the outstanding warrants to purchase convertible preferred stock converted into warrants to purchase 40,454 shares of common stock at an average exercise price of $12.36 per share. The Company remeasured the fair value of these remaining warrants at the date of the conversion and recorded a $42,000 loss related to the change in fair value as part of interest expense and other, net, and reclassified the fair value of $286,000 to additional paid-in capital. The following table presents activity in the preferred stock warrant liability during the three-month period ended March 31, 2014.


	Fair value at December 31, 2013	$	244
	Change in estimated fair value of convertible preferred warrant liability recorded as interest expense and other, net		42
	Reclassification to additional paid-in capital upon conversion of convertible preferred stock warrants to common stock warrants		(286	)

	Fair value at March 31, 2014	$	—

Balance_Sheet_Components

Balance Sheet Components	3 Months Ended
Balance Sheet Components	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Balance Sheet Components	'
	4. Balance Sheet Components
	Accrued Liabilities
	Accrued liabilities consisted of the following (in thousands):


		March 31,		December 31,
		2014		2013
	Accrued clinical and development expenses	$	1,254	$	1,429
	Payroll and related expenses		957		760
	Other		621		815

		$	2,832	$	3,004

License_and_Collaboration_Agre

License and Collaboration Agreements	3 Months Ended
License and Collaboration Agreements	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
License and Collaboration Agreements	'
	5. License and Collaboration Agreements
	Isis Pharmaceuticals
	In January 2006, the Company entered into a license agreement with Isis Pharmaceuticals, Inc. (“Isis”). Isis granted the Company an exclusive, worldwide license with the right to grant and authorize sublicenses related to the research and development of aminoglycoside products. As an up-front fee, the Company issued 97,402 shares of preferred Series A convertible stock at a fair value of $15.40 per share. This license fee of $1,500,000 was recorded as research and development expense in 2006. In further consideration of this license, and in accordance with the terms of the agreement, the Company will be required to make milestone payments with respect to development, regulatory and commercialization milestones, and to pay a percentage of revenue received from sublicensees (if any). All such milestone and sublicense revenue payments may total, in the aggregate, up to but no more than $19,500,000 for the first product, including a payment of $4,000,000 that the Company will make to Isis following dosing the first patient in the Company’s Phase 3 trial of plazomicin, and $9,750,000 following the second product commercialized under the agreement with Isis. The Company is also required to pay additional milestone payments of up to $20,000,000 in the aggregate upon the first achievement of specified threshold levels of annual net sales of all aminoglycoside products in a calendar year. The license agreement also provides that the Company shall pay royalties equal to a low single-digit percentage of annual worldwide net sales of all licensed products, including plazomicin.
	Cumulative to date, the Company has compensated Isis $3,000,000 in connection with the first two milestones under the license for the first aminoglycoside product. There are no outstanding payments due as of March 31, 2014 and December 31, 2013.

Government_Contracts

Government Contracts	3 Months Ended
Government Contracts	Mar. 31, 2014
Contractors [Abstract]	'
Government Contracts	'
	6. Government Contracts
	Certain of the Company’s drug discovery and development activities are performed under contracts with U.S. government agencies. Management has determined that the Company is the principal participant in the following contract arrangements, and, accordingly, the Company records amounts earned under the arrangements as revenue.

	Biomedical Advanced Research and Development Authority
	In August 2010, the Company was awarded a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for the development, manufacturing, nonclinical and clinical evaluation of, and regulatory filings for, plazomicin as a countermeasure for disease caused by antibiotic-resistant pathogens and biothreats. The original contract included committed funding of $27,600,000 for the first two years of the contract and subsequent options exercisable by BARDA to provide additional funding. In September 2012, BARDA modified the contract to increase the total contract committed funding to $43,398,000 through March 2014. In April 2013, the Company was awarded an additional $60,410,000 under the contract to support its Phase 3 clinical trial of plazomicin to increase the total committed funding under this contract to $103,808,000. The Company recorded revenues of $5,988,000 and $3,228,000 under this agreement during the three-month periods ended March 31, 2014 and 2013, respectively.
	Defense Threat Reduction Agency
	In November 2012, the Defense Threat Reduction Agency (“DTRA”) terminated for convenience a contract with the Company that provided funding for the Company’s LpxC inhibitor program. In connection with the termination, the Company is seeking payment from DTRA for additional expenses the Company has incurred. The Company cannot be certain that it will be able to prevail upon DTRA to make such payments or that the Company would be successful in any subsequent legal proceeding to challenge DTRA’s decision.
	In connection with the Company’s claim for payment from DTRA, the Company is undergoing an audit by the Defense Contract Audit Agency (“DCAA”), of the expenses for which the Company is seeking payment, as well as of $33,480,000 previously paid to the Company under the DTRA contract. The results of the audit may lead certain expenses to be disallowed under the contract, which may reduce the size of any payment the Company may receive from DTRA, or may require the Company to refund some of the previously paid amounts the Company received from DTRA, which would adversely affect the Company’s financial position and results of operations.
	U.S. Army Medical Research Acquisition Authority
	In May 2012, the Company was awarded a one-year, $2,499,000 contract by the U.S. Army Medical Research Acquisition Authority to support its Phase 1 clinical study of ACHN-975, a product candidate from its LpxC inhibitor program. The Company recorded revenues of zero and $220,000 under this agreement during the three-month periods ended March 31, 2014 and 2013, respectively. There were no outstanding receivables due as of March 31, 2014.

Borrowings

Borrowings	3 Months Ended
Borrowings	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Borrowings	'
	7. Borrowings
	Oxford Finance and SVB Loan Agreement
	In November 2011, the Company entered into a loan and security agreement (the “Loan Agreement”) with Oxford Finance LLC and Silicon Valley Bank (“SVB”), under which the Company could borrow up to $12,000,000 through June 30, 2012, with $8,000,000 being drawable by the Company at its option, and the remaining $4,000,000 being drawable upon the occurrence of an IND Event, as defined in the Loan Agreement.
	The Company borrowed $4,000,000 in November 2011, and the remaining $8,000,000 in April 2012, upon the occurrence of an IND Event.
	The interest rate, which was fixed at the closing of each tranche, equals the three-month LIBOR plus 7.75%. The interest rates for the tranches under the Loan Agreement are 8.18% and 8.22% per annum. Payments are monthly in arrears and interest only until September 1, 2012, followed by 30 equal monthly payments of principal and interest through the scheduled maturity date of February 1, 2015. In addition, a final payment equal to 8.25% of the aggregate amount drawn will be due on February 1, 2015, or upon termination of the Loan Agreement, which is being accreted as interest expense over the term of the loan using the effective-interest method.
	In accordance with the terms of the Loan Agreement, the Company agreed to issue warrants to Oxford Finance LLC and SVB upon each drawdown to purchase preferred stock equal to 3% of the advanced amount using a share strike price equal to the lower of the price per share of the Company’s Series C convertible preferred stock or the price per share in its next round convertible preferred stock financing. During 2011 and 2012, the Company issued warrants to Oxford Finance LLC and SVB to purchase 10,008 and 20,016 shares, respectively, of its Series C convertible preferred stock at an exercise price of $11.99 per share. The fair value of these warrants at the date of issuance was approximately $86,000 and $163,000 and was recorded as a debt discount and is being amortized as interest expense over the term of the loan using the effective-interest method.

	As of December 31, 2013, these warrants remained outstanding and exercisable. Immediately prior to the closing of the IPO, these warrants automatically converted into warrants exercisable for shares of common stock, resulting in the reclassification of the related preferred stock warrant liabilities to additional paid-in capital.
	The loans are secured by substantially all of the Company’s assets, except for intellectual property. Under the Loan Agreement, the Company also agreed to certain restrictions regarding the pledging or encumbrance of its intellectual property. The Loan Agreement includes customary administrative covenants, but does not include any financial maintenance or operating related covenants. As of March 31, 2014, the Company was in compliance with all required covenants. The Company recorded interest expense related to the loan of $162,000 and $311,000 for the three-month periods ended March 31, 2014 and 2013, respectively. The annual effective interest rates of the notes payable, including the accretion of the final payments, are approximately 11.9%–13.1%.
	Funding Agreement with The Wellcome Trust
	In March 2010, the Company entered into a Funding Agreement (the “2010 Wellcome Funding Agreement”), with The Wellcome Trust Limited, a company registered in England and Wales, as trustee for The Wellcome Trust (the “Trust”). Under the 2010 Wellcome Funding Agreement, the Trust provided an unsecured convertible loan of $5,594,000 to the Company to progress its aminoglycoside program. The funds were advanced to the Company in two tranches of (a) $3,148,000 upon the signing of the 2010 Wellcome Funding Agreement and (b) the remaining amount upon the satisfaction of a milestone defined under the 2010 Wellcome Funding Agreement.
	The Trust, at its discretion, had the right to convert any outstanding balance on the loan into the Company’s stock at a conversion price representing a 20% discount to the applicable share price: (a) after the first round of equity financing following the execution of the 2010 Wellcome Funding Agreement, using the share price from such round; (b) immediately prior to the completion of a sale of the Company, using the price per share paid in the sale; (c) in case of an IPO, prior to the admission to the trading of the Company’s common stock on the applicable exchange, using the share price in the IPO; and (d) in certain other circumstances, including the occurrence of an event of default, using the share price from the first round of equity financing following the execution of the 2010 Wellcome Funding Agreement, or if such has not yet occurred, using a share price determined by independent accountants appointed jointly by the parties. In addition, the Trust also had the right to demand repayment of the entire loan amount or part of the loan together with accrued interest, which accrued at the rate of 2% per annum above the three-month dollar LIBOR, upon the occurrence of certain circumstances related to a sale or IPO of the Company or in the event of default of the 2010 Wellcome Funding Agreement. In addition, the Trust was able to demand repayment of such amounts at any time after the third anniversary of the end of the drawdown period. However, the Trust could not require the Company to repay the loan and accrued interest if, as a result of such repayment, the Company would likely become insolvent.
	The discount feature of the loan, and the control of conversion by the lender under this funding agreement created a beneficial conversion feature (“BCF”), which is accounted for as derivative liability and recorded in long-term liabilities. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid-in capital, resulting in a discount on the convertible instrument. The fair value of the BCF is measured by multiplying (1) the intrinsic value of the 20% conversion discount on the effective date with (2) the number of shares converted.
	In March 2013, the outstanding balance of the 2010 Wellcome Funding Agreement of $5,594,000, was converted into Series D convertible preferred stock at a conversion price that represented a 20% discount to the issue price. The debt discount was accreted over the life of the debt up to date of redemption, and the Company recorded interest expense related to the 2010 Wellcome Funding Agreement of $153,000 for the three-month period ended March 31, 2013.
	Convertible Notes Purchase Agreement
	In November 2012, the Company entered into a Note Purchase Agreement (the “2012 Bridge Loan Agreement”) with a group of existing investors. Under the 2012 Bridge Loan Agreement, the investors severally agreed to purchase convertible promissory notes for a principal amount of up to $3,000,000 in aggregate. For value received, the Company agreed to pay to the investors the principal loan amount plus accrued interest calculated at a rate equal to 6% per annum, computed on the basis of the actual days elapsed and a year of 365 days, on the earlier of (a) May 31, 2013 or (b) when such amounts become automatically due and payable or are declared due and payable by the investors upon default.
	On March 6, 2013, the investors under the 2012 Bridge Loan Agreement converted the entire outstanding notes amount plus accrued interest into shares of the Company’s Series D convertible preferred stock at a conversion price of $11.99 per share, which was the issuance price of Series D convertible preferred stock. The Company issued 227,784 shares of Series D convertible preferred stock to the investors upon conversion of outstanding loans and accrued interest in the aggregate of $2,732,000 under the 2012 Bridge Loan Agreement.

Equity_Incentive_Plans

Equity Incentive Plans	3 Months Ended
Equity Incentive Plans	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Equity Incentive Plans	'
	8. Equity Incentive Plans
	In 2003, the Company adopted the Achaogen, Inc. Stock Incentive Plan (the “2003 Plan”) under which it may grant incentive stock options (“ISOs”), nonqualified stock options, restricted stock, and stock grants. The options expire ten years after the grant date. As of March 31, 2014, there are no shares reserved for future awards under the 2003 Plan. Any such shares of common stock that are subject to awards under the 2003 Plan which are forfeited or lapse unexercised and which are not issued under the 2003 Plan will be available for issuance under the Company’s 2014 Equity Incentive Award Plan (the “2014 Plan”).
	In February 2014, the Company’s stockholders approved the 2014 Plan, which became effective as of March 11, 2014. Under the 2014 Plan, the Company may grant ISOs, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units awards and other stock-based awards for the purchase of that number of shares of common stock equal to the sum of (i) 963,636 shares of common stock, (ii) 121,555 shares of common stock that were reserved for issuance under the 2003 Plan that remained available for issuance under the 2003 Plan immediately prior to effectiveness of the 2014 Plan and (iii) any shares of common stock subject to awards under the 2003 Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company without having been fully exercised or resulting in any common stock being issued. In addition, the number of shares of common stock that may be issued under the 2014 Plan is subject to an annual increases, to be added on January 1 of each year beginning in 2015 and ending in 2024, in each case subject to the approval of the board of directors or the compensation committee of the board of directors, equal to the lesser of (i) 4% of the shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such smaller number of shares of stock as determined by the Company’s board of directors; provided, however, that no more than 14,545,454 shares of stock may be issued under the 2014 Plan upon the exercise of ISOs. As of March 31, 2014, 951,564 shares were available for future issuance under the 2014 Plan.
	Under the 2014 Plan, terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2014 Plan. Options granted by the Company typically vest over a four year period and the exercise price may not be less than fair market value on the date of grant. Certain of the options are subject to acceleration of vesting in the event of certain change of control transactions. The options are exercisable from the date of grant for a period of ten years.
	In February 2014, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (the “ESPP”), which became effective as of March 11, 2014. The number of shares of common stock initially reserved for issuance under the ESPP was 145,454 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2015 and ending in 2024, in each case subject to the approval of the board of directors or the compensation committee of the board of directors, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) such number of shares as determined by the board of directors; provided, however, that no more than 3,181,818 shares of common stock may be issued under the ESPP. As of March 31, 2014, no shares of common stock had been issued under the ESPP and 145,454 shares remained available for future issuance under the ESPP.
	The following table summarizes stock option activity under the stock plans and related information (in thousands except share and per share data):


		Shares			Options			Weighted-		Weighted-
		available			Outstanding			Average		Average
		for grant						Exercise		Remaining
								Price		Contractual
										Term
										(years)
	Balance at December 31, 2013		127,277			1,405,550		$	5.68		7.56
	Additional shares authorized		1,190,908
	Options granted		(440,903	)		440,903		$	10.82
	Options forfeited		74,282			(74,282	)	$	4.73

	Balance at March 31, 2014		951,564			1,772,171		$	7		7.87


	Stock-based compensation expense recognized for stock options granted to employees and non-employees in the Company’s condensed consolidated statements of operations was as follows (in thousands):


		Three-Month Periods
		Ended March 31,
		2014			2013
	Research and development	$	151		$	84
	General and administrative		216			240

	Total	$	367		$	324

	As of March 31, 2014, approximately $4,031,000 of total unrecognized share-based compensation expense related to unvested share options is expected to be recognized over a weighted-average period of 2.93 years.
	The estimated grant date fair value of employee stock options was calculated using the Black-Scholes valuation model, based on the following assumptions:


		Three Months Ended
		March 31,
		2014			2013
	Expected term (years)		5.3-6.1			—
	Volatility		76-77	%		—
	Risk-free interest rate		1.7-1.9	%		—
	Expected dividend yield		—			—

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation and Consolidation (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. The results of operations for the three-month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December 31, 2013 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
	The accompanying condensed financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2013 included in the Company’s Prospectus filed pursuant to Rule 424(b)(4) on March 12, 2014 with the SEC (the “Prospectus”).
Initial Public Offering	'
	Initial Public Offering
	In March 2014, the Company completed its initial public offering (“IPO”) of shares of its common stock, pursuant to which the Company issued 6,900,000 shares of common stock, which includes 900,000 shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately $73.9 million, after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the completion of our IPO, all shares of convertible preferred stock converted into 10,386,894 shares of common stock and all of the Company’s convertible preferred stock warrants were converted into warrants to purchase common stock.
Use of Estimates	'
	Use of Estimates
	The accompanying financial statements have been prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent liabilities. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of liabilities, convertible preferred stock and related warrants, common stock and stock-based awards and income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.
Reverse Stock Split	'
	Reverse Stock Split
	On February 20, 2014, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-11 reverse split of its common stock (the “Reverse Split”). The Company effected this amendment to its certificate of incorporation on March 10, 2014. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to the condensed consolidated financial statements have been adjusted within the condensed consolidated financial statements, on a retroactive basis, to reflect the Reverse Split.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, contracts receivable, prepaid and other current assets, accounts payable, accrued liabilities, and certain related-party convertible notes payable approximate fair value due to their short-term maturities.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and other highly liquid investments with original maturities of three months or less from the date of purchase.
Restricted Cash	'
	Restricted Cash
	At March 31, 2014 and December 31, 2013, the Company had long-term restricted cash of $127,000. The restricted cash, which consists of a money market account with one of the Company’s financial institutions, serves as collateral for a letter of credit provided as a security deposit under the Company’s facility lease. The facility lease expires on April 14, 2017.
Segment Reporting	'
	Segment Reporting
	The Company has one operating segment.
Customer Concentration	'
	Customer Concentration
	For the three-month periods ended March 31, 2014 and 2013, all of the Company’s revenue has been generated solely from funding pursuant to U.S. government contracts, and accordingly all contracts receivable relate to funding from U.S. government contracts.
Convertible Preferred Stock Warrant Liabilities	'
	Convertible Preferred Stock Warrant Liabilities
	The Company accounted for its Series A and Series C convertible preferred stock warrant liabilities as freestanding warrants for shares that are puttable or redeemable. At December 31, 2013, these warrants were classified as liabilities on the consolidated balance sheets at their estimated fair value, and at the end of each reporting period, changes in estimated fair value during the period were recorded as a component of interest expense and other, net. At the time of the IPO, the warrants to purchase preferred stock converted into warrants to purchase common stock, which are no longer subject to remeasurement.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue when: (i) evidence of an arrangement exists, (ii) fees are fixed or determinable, (iii) services have been delivered, and (iv) collectability is reasonably assured. The Company currently generates revenue entirely from government contracts. Government contracts are agreements that provide the Company with payments for certain types of expenditures in return for research and development activities over a contractually defined period. Revenue from government contracts is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable conditions under the government contracts have been met.

	Funds received from third parties under contract arrangements are recorded as revenue if the Company is deemed to be the principal participant in the contract arrangements because the activities under the contracts are part of the Company’s development programs. If the Company is not the principal participant, the funds from contracts are recorded as a reduction to research and development expense. Contracts funds received are not refundable and are recognized when the related qualified research and development costs are incurred and when there is reasonable assurance that the funds will be received. Funds billed and received in advance are recorded as deferred revenue.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per common share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. For purposes of this calculation, preferred stock, stock options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Because the Company has reported a net loss in all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
	Effective as of the completion of the IPO, all of the Company’s preferred stock was converted to common stock. For purposes of calculating net loss per common share for the three-month period ended March 31, 2014, the preferred stock converted to common stock was included in the net loss per common share calculation on a post-conversion basis based on the conversion date.
	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):


		March 31,
		2014		2013
	Convertible preferred stock		—		9,404,574
	Warrants to purchase convertible preferred stock		—		40,454
	Options to purchase common stock		1,772,171		1,340,433
	Warrants to purchase common stock		40,454		909

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding	'
	The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):


		March 31,
		2014		2013
	Convertible preferred stock		—		9,404,574
	Warrants to purchase convertible preferred stock		—		40,454
	Options to purchase common stock		1,772,171		1,340,433
	Warrants to purchase common stock		40,454		909

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Financial Assets Measured and Recognized at Fair Value	'
	As of March 31, 2014 and December 31 2013, financial assets measured and recognized at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above were as follows (in thousands):
	As of March 31, 2014:


		Level 1			Level 2		Level 3		Total
		(in thousands)
	Assets
	Cash	$	12,610		$	—	$	—	$	12,610
	Money market funds		72,327			—		—		72,327
	Restricted cash		127			—		—		127

		$	85,064		$	—	$	—	$	85,064

	Reported as:
	Cash and cash equivalents	$	84,937

	Restricted cash	$	127

	As of December 31, 2013:


		Level 1			Level 2		Level 3		Total
		(in thousands)
	Assets
	Cash	$	8,411		$	—	$	—	$	8,411
	Money market funds		2,327			—		—		2,327
	Restricted cash		127			—		—		127

		$	10,865		$	—	$	—	$	10,865

	Reported as:
	Cash and cash equivalents	$	10,738

	Restricted cash	$	127

	Liabilities
	Convertible preferred stock warrant liabilities	$	—		$	—	$	244	$	244

Activity in Preferred Stock Warrant Liability	'
	The following table presents activity in the preferred stock warrant liability during the three-month period ended March 31, 2014.


	Fair value at December 31, 2013	$	244
	Change in estimated fair value of convertible preferred warrant liability recorded as interest expense and other, net		42
	Reclassification to additional paid-in capital upon conversion of convertible preferred stock warrants to common stock warrants		(286	)

	Fair value at March 31, 2014	$	—

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	3 Months Ended
Balance Sheet Components (Tables)	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consisted of the following (in thousands):


		March 31,		December 31,
		2014		2013
	Accrued clinical and development expenses	$	1,254	$	1,429
	Payroll and related expenses		957		760
	Other		621		815

		$	2,832	$	3,004

Equity_Incentive_Plans_Tables

Equity Incentive Plans (Tables)	3 Months Ended
Equity Incentive Plans (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock Option Activity	'
	The following table summarizes stock option activity under the stock plans and related information (in thousands except share and per share data):


		Shares			Options			Weighted-		Weighted-
		available			Outstanding			Average		Average
		for grant						Exercise		Remaining
								Price		Contractual
										Term
										(years)
	Balance at December 31, 2013		127,277			1,405,550		$	5.68		7.56
	Additional shares authorized		1,190,908
	Options granted		(440,903	)		440,903		$	10.82
	Options forfeited		74,282			(74,282	)	$	4.73

	Balance at March 31, 2014		951,564			1,772,171		$	7		7.87

Schedule of Stock-based Compensation Expense for Stock Options Granted to Employees and Non-employees	'
	Stock-based compensation expense recognized for stock options granted to employees and non-employees in the Company’s condensed consolidated statements of operations was as follows (in thousands):


		Three-Month Periods
		Ended March 31,
		2014			2013
	Research and development	$	151		$	84
	General and administrative		216			240

	Total	$	367		$	324

Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model	'
	The estimated grant date fair value of employee stock options was calculated using the Black-Scholes valuation model, based on the following assumptions:


		Three Months Ended
		March 31,
		2014			2013
	Expected term (years)		5.3-6.1			—
	Volatility		76-77	%		—
	Risk-free interest rate		1.7-1.9	%		—
	Expected dividend yield		—			—

Organization_and_Basis_of_Pres2

Organization and Basis of Presentation and Consolidation - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Initial public offering, share issued	6,900,000
Shares issued for underwriters' granted of their over-allotment option	900,000
Net proceeds from initial public offering	$73.90
Preferred shares converted	10,386,894

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Feb. 20, 2014	Mar. 31, 2014	Dec. 31, 2013
	Feb. 20, 2014	Segment	Dec. 31, 2013
Accounting Policies [Abstract]	'	'	'
Reverse split of Common Stock	'	'1-for-11	'
Reverse split of Common Stock, conversion ratio	0.090909091	'	'
Restricted cash	'	$127	$127
Facility lease expiration date	'	14-Apr-17	'
Number of operating segments	'	1	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities outstanding	'	9,404,574
Warrants to Purchase Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities outstanding	'	40,454
Options to Purchase Common Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities outstanding	1,772,171	1,340,433
Warrants to Purchase Common Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities outstanding	40,454	909

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'
Fair value, transfers between levels	$0
Convertible Preferred Stock Warrant Liabilities [Member]	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'
Increase in fair value recognized in net loss	42
Reclassification of fair value to additional paid-in capital	($286)
Warrants to Purchase Common Stock [Member]	'
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]	'
Warrants to purchase common stock	40,454
Warrants to purchase common stock, exercise price	12.36

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets Measured and Recognized at Fair Value (Detail) (USD $)

Mar. 31, 2014

Dec. 31, 2013

In Thousands, unless otherwise specified

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Level 1 [Member]

Level 2 [Member]

Level 3 [Member]

Fair Value, Measurements, Recurring [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Reported [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Convertible Preferred Stock Warrant Liabilities [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Level 1 [Member]

Level 2 [Member]

Level 3 [Member]

Restricted Cash [Member]

Cash and Cash Equivalents [Member]

Convertible Preferred Stock Warrant Liabilities [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Reported [Member]

Convertible Preferred Stock Warrant Liabilities [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Convertible Preferred Stock Warrant Liabilities [Member]

Cash [Member]

Money Market Funds [Member]

Restricted Cash [Member]

Cash and Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets, Fair Value

$85,064

$12,610

$72,327

$127

$85,064

$12,610

$72,327

$127

$84,937

$10,865

$8,411

$2,327

$127

$10,865

$8,411

$2,327

$127

$10,738

Liabilities

Liabilities, Fair Value

$244

Fair_Value_Measurements_Prefer

Fair Value Measurements - Preferred Stock Warrant Liability (Detail) (Convertible Preferred Stock Warrant Liabilities [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Convertible Preferred Stock Warrant Liabilities [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Fair value, Beginning Balance	$244
Change in estimated fair value of convertible preferred warrant liability recorded as interest expense and other, net	42
Reclassification to additional paid-in capital upon conversion of convertible preferred stock warrants to common stock warrants	-286
Fair value, Ending Balance	'

Balance_Sheet_Components_Sched

Balance Sheet Components - Schedule of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accrued clinical and development expenses	$1,254	$1,429
Payroll and related expenses	957	760
Other	621	815
Accrued liabilities	$2,832	$3,004

License_and_Collaboration_Agre1

License and Collaboration Agreements - Additional Information (Detail) (USD $)	3 Months Ended			1 Months Ended	3 Months Ended		1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Jan. 31, 2006	Mar. 31, 2014	Dec. 31, 2013	Jan. 31, 2006	Jan. 31, 2006	Jan. 31, 2006
				Isis Pharmaceuticals License Agreement [Member]	Isis Pharmaceuticals License Agreement [Member]	Isis Pharmaceuticals License Agreement [Member]	Isis Pharmaceuticals License Agreement [Member]	Isis Pharmaceuticals License Agreement [Member]	Isis Pharmaceuticals License Agreement [Member]
							Up-front License Fee [Member]	Up-front License Fee [Member]	First Patient [Member]
								Series A Convertible Preferred Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'	'	'	'
Issuance of convertible preferred stock related to license agreement, shares	'	'	'	'	'	'	'	97,402	'
Shares issued price per share	'	'	'	'	'	'	'	$15.40	'
Research and development expense	$6,605,000	$4,661,000	'	'	'	'	$1,500,000	'	'
Milestone payments for first commercialization product	'	'	'	19,500,000	'	'	'	'	4,000,000
Milestone payments for second commercialization product	'	'	'	9,750,000	'	'	'	'	'
Aggregate additional milestone payments	'	'	'	20,000,000	'	'	'	'	'
Cumulative milestones compensation	'	'	'	'	3,000,000	'	'	'	'
Contracts receivable	$6,027,000	'	$7,230,000	'	$0	$0	'	'	'

Government_Contracts_Additiona

Government Contracts - Additional Information (Detail) (USD $)	1 Months Ended			1 Months Ended			3 Months Ended		1 Months Ended	3 Months Ended
	Nov. 30, 2012	Mar. 31, 2014	Dec. 31, 2013	Apr. 30, 2013	Sep. 30, 2012	Aug. 31, 2010	Mar. 31, 2014	Mar. 31, 2013	31-May-12	Mar. 31, 2014	Mar. 31, 2013
	Nov. 30, 2012	Mar. 31, 2014	Dec. 31, 2013	Biomedical Advanced Research and Development Authority [Member]	Biomedical Advanced Research and Development Authority [Member]	Biomedical Advanced Research and Development Authority [Member]	Biomedical Advanced Research and Development Authority [Member]	Biomedical Advanced Research and Development Authority [Member]	U.S. Army Medical Research Acquisition Authority [Member]	U.S. Army Medical Research Acquisition Authority [Member]	U.S. Army Medical Research Acquisition Authority [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Research and development contract	'	'	'	$103,808,000	$43,398,000	$27,600,000	'	'	$2,499,000	'	'
Term of agreement	'	'	'	'	'	'2 years	'	'	'1 year	'	'
Expiration date	'	'	'	'	'2014-03	'	'	'	'	'	'
Increase in research and development contract	'	'	'	60,410,000	'	'	'	'	'	'	'
Recognized revenues	'	'	'	'	'	'	5,988,000	3,228,000	'	0	220,000
Claim for payment from DTRA	33,480,000	'	'	'	'	'	'	'	'	'	'
Contracts receivable	'	$6,027,000	$7,230,000	'	'	'	'	'	'	$0	'

Borrowings_Additional_Informat

Borrowings - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Nov. 30, 2012

Mar. 06, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2010

Apr. 30, 2012

Nov. 30, 2011

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2014

2012 Bridge Loan Agreement [Member]

Series D Convertible Preferred Stock [Member]

2010 Wellcome Funding Agreement [Member]

LIBOR [Member]

Oxford Finance LLC and SVB [Member]

2012 Bridge Loan Agreement [Member]

2010 Wellcome Funding Agreement [Member]

Installment

First Tranche [Member]

Second Tranche [Member]

Warrants To Purchase Series C Convertible Preferred Stock [Member]

LIBOR [Member]

Debt Instrument [Line Items]

Loan borrowing capacity, maximum

$12,000,000

Loan borrowing capacity, unconditional

8,000,000

Loan borrowing capacity, drawable upon the occurrence of an IND Event

4,000,000

Loan borrowed

8,000,000

4,000,000

Debt instrument interest rate added to LIBOR rate

2.00%

7.75%

Debt, stated interest rate

8.18%

8.22%

Debt, number of installments

Loan agreement maturity date

1-Feb-15

Debt, stated interest rate at maturity date

8.25%

Warrants to purchase shares of stock, shares

20,016

10,008

Warrants to purchase shares of stock, shares, exercise price per share

11.99

Fair value of warrants

163,000

86,000

Warrants issued, percentage of advances

3.00%

Interest expense on convertible debt

72,000

140,000

153,000

162,000

311,000

Annual effective interest rate, minimum

11.90%

Annual effective interest rate, maximum

13.10%

Unsecured convertible loan

5,594,000

Funding agreement, description

'The funds were advanced to the Company in two tranches of (a) $3,148,000 upon the signing of the 2010 Wellcome Funding Agreement and (b) the remaining amount upon the satisfaction of a milestone defined under the 2010 Wellcome Funding Agreement.

Debt amount released upon signing of agreement

3,148,000

Percentage of conversion price discount on common stock

20.00%

Debt conversion, description

'The right to convert any outstanding balance on the loan into the Company's stock at a conversion price representing a 20% discount to the applicable share price:(a) after the first round of equity financing following the execution of the 2010 Wellcome Funding Agreement, using the share price from such round; (b) immediately prior to the completion of a sale of the Company, using the price per share paid in the sale; (c) in case of an IPO, prior to the admission to the trading of the Companybs common stock on the applicable exchange, using the share price in the IPO; and (d) in certain other circumstances, including the occurrence of an event of default, using the share price from the first round of equity financing following the execution of the 2010 Wellcome Funding Agreement, or if such has not yet occurred, using a share price determined by independent accountants appointed jointly by the parties.

Fair value intrinsic rate

20.00%

Converted into Series D convertible preferred stock

5,594,000

Convertible promissory notes

3,000,000

Debt, effective interest rate

6.00%

Debt instrument maturity date description

'The basis of the actual days elapsed and a year of 365 days, on the earlier of (a) May 31, 2013 or (b) when such amounts become automatically due and payable or are declared due and payable by the investors upon default.

Convertible preferred stock, conversion price per share

$11.99

Convertible preferred stock issued on conversion

227,784

Convertible preferred stock amount on conversion

$2,732,000

Equity_Incentive_Plans_Additio

Equity Incentive Plans - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	3 Months Ended			1 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Feb. 28, 2014	Mar. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Feb. 28, 2014	Mar. 31, 2014
	Mar. 31, 2014	Dec. 31, 2013	Employee Stock Purchase Plan [Member]	Employee Stock Purchase Plan [Member]	Stock Incentive Plan 2003 [Member]	Stock Incentive Plan 2003 [Member]	2014 Equity Incentive Award Plan [Member]	2014 Equity Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Option expiration period	'10 years	'	'	'	'10 years	'	'	'
Outstanding shares available for future issuance	951,564	127,277	145,454	145,454	0	121,555	'	951,564
Shares authorized for issuance under stock incentive plan	'	'	'	'	'	'	963,636	'
Increase in shares of common stock reserved for issuance	'	'	3,181,818	'	'	'	14,545,454	'
Percentage of shares of common stock outstanding	'	'	1.00%	'	'	'	4.00%	'
Vesting period	'4 years	'	'	'	'	'	'	'
Common stock, shares issued	'	'	'	0	'	'	'	'
Unrecognized share-based compensation	$4,031,000	'	'	'	'	'	'	'
Weighted-average period of cost expected to be recognized	'2 years 11 months 5 days	'	'	'	'	'	'	'

Equity_Incentive_Plans_Summary

Equity Incentive Plans - Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Shares available for grant, Beginning balance	127,277	'
Shares available for grant, Additional shares authorized	1,190,908	'
Shares available for grant, Options granted	-440,903	'
Shares available for grant, Options forfeited	74,282	'
Shares available for grant, Ending balance	951,564	127,277
Options Outstanding, Beginning balance	1,405,550	'
Options Outstanding, Options granted	440,903	'
Options Outstanding, Options forfeited	-74,282	'
Options Outstanding, Ending balance	1,772,171	1,405,550
Weighted-Average Exercise Price, Beginning balance	$5.68	'
Weighted-Average Exercise Price, Options granted	$10.82	'
Weighted-Average Exercise Price, Options forfeited	$4.73	'
Weighted-Average Exercise Price, Ending balance	$7	$5.68
Weighted-Average Remaining Contractual Term, balance	'7 years 10 months 13 days	'7 years 6 months 22 days

Equity_Incentive_Plans_Schedul

Equity Incentive Plans - Schedule of Stock-based Compensation Expense for Stock Options Granted to Employees and Non-employees (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation expense	$367	$324
Research and Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation expense	151	84
General and Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation expense	$216	$240

Equity_Incentive_Plans_Schedul1

Equity Incentive Plans - Schedule of Estimated Grant Date Fair Value of Employee Stock Options Using Black-Scholes Valuation Model (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]	'	'
Volatility, minimum	76.00%	'
Volatility, maximum	77.00%	'
Risk-free interest rate, minimum	1.70%	'
Risk-free interest rate, maximum	1.90%	'
Expected dividend yield	'	'
Minimum [Member]	'	'
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]	'	'
Expected term (years)	'5 years 3 months 18 days	'
Maximum [Member]	'	'
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]	'	'
Expected term (years)	'6 years 1 month 6 days	'